Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?

<table>Imaging and pathologic outcomes of 148 patients with 151 Stage I–III triple negative breast cancers (TNBCs) undergoing neoadjuvant chemotherapy prior to definitive surgical intervention.</table>

Journal of Oncology

fig1

Figure 1

Figure 1: Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer? 